SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CytRx Oncology Corp – ‘8-K’ for 6/16/08

On:  Wednesday, 6/18/08, at 4:18pm ET   ·   For:  6/16/08   ·   Accession #:  950123-8-7030   ·   File #:  0-51534

Previous ‘8-K’:  ‘8-K’ on 6/9/08 for 6/6/08   ·   Latest ‘8-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/18/08  CytRx Oncology Corp               8-K:5       6/16/08    1:10K                                    RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     12K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  FORM 8-K  

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2008
     
INNOVIVE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   000-51534   74-3123261
(State or other jurisdiction of incorporation)   (Commission File
Number)
  (IRS Employer ID Number)
     
555 Madison Avenue, 25th Floor, New York, New York 10022
(Address of principal executive offices)            (Zip Code)
Registrant’s telephone number, including area code (212) 716-1810
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 



 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
     (b) On June 16, 2008, Angelo DeCaro, a member of the Board of Directors of Innovive Pharmaceuticals, Inc. (the “Company”) notified the Company that he resigned as a member of the Board effective June 16, 2008. His resignation was not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 



 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  INNOVIVE PHARMACEUTICALS, INC.
 
 
Date: June 18, 2008  /s/ Steven Kelly    
  Steven Kelly   
  President and Chief Executive Officer   
 

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:6/18/08None on these Dates
For Period End:6/16/08
 List all Filings 
Top
Filing Submission 0000950123-08-007030   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:34:37.2am ET